Iceland· IS-EU/1/16/1086/002 & EU/1/16/1086/004
Tagrisso
A osimertinib product containing osimertinibum inn mesylat, registered in Iceland by AstraZeneca AB*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Osimertinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EB04 (osimertinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Osimertinib · ATC L01EB04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of osimertinib costs, country by country.
Normalised to the WHO defined daily dose (80 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Osimertinib · price per daily dose (80 mg)
USD · FX 28 Sept 2026
- CH Switzerland$219.08
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Osimertinibum INN mesylat
- Manufacturer
- AstraZeneca AB*
- Country
- Iceland (IS)
- ATC code
- L01EB04
- ATC class
- Osimertinib
- Defined daily dose
- 80 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean45679530 stk x1 stsk.þISK 890974
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
543 interactions on record for osimertinib.
Graded by severity as the source publishes them — 284 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Osimertinib · interactions on record
543 records
- 284 severe
- 251 moderate
- 8 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Osimertinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTAGRISSOAstraZeneca Pharmaceuticals LP
- CzechiaTAGRISSOAstraZeneca AB, Södertälje
- FinlandTAGRISSOAstraZeneca AB
- FranceTAGRISSO 80 mg, comprimé pelliculéASTRAZENECA AB
- BelgiumTagrisso 80 mgAstraZeneca
- NetherlandsTagrisso 80 mg, filmomhulde tablettenAstraZeneca AB
- NorwayTagrissoAstraZeneca AB (2)
- PolandTagrissoAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Tagrisso
- Norway · Tagrisso
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eca5c813-4566-4247-9724-153fa285ca91 GET /v1/drugs/eca5c813-4566-4247-9724-153fa285ca91?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01EB04",
"marketed": true,
"strength": "80 mg",
"ma_number": "EU/1/16/1086/002 & EU/1/16/1086/004",
"substance": "Osimertinibum INN mesylat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42402"
}See everything about osimertinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.